<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">ssmu</journal-id><journal-title-group><journal-title xml:lang="ru">Бюллетень сибирской медицины</journal-title><trans-title-group xml:lang="en"><trans-title>Bulletin of Siberian Medicine</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1682-0363</issn><issn pub-type="epub">1819-3684</issn><publisher><publisher-name>Siberian State Medical University, the Ministry of Healthcare of the Russian Federation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.20538/1682-0363-2023-4-57-64</article-id><article-id custom-type="elpub" pub-id-type="custom">ssmu-5418</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL PAPERS</subject></subj-group></article-categories><title-group><article-title>Клинико-патологические особенности рака толстой кишки в зависимости от dMМR статуса опухоли</article-title><trans-title-group xml:lang="en"><trans-title>Clinicopathological features of colon cancer depending on the dMMR status of the tumor</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3868-2310</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Наумов</surname><given-names>С. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Naumov</surname><given-names>S. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Наумов Сергей Сергеевич – врач-патологоанатом, клиники СибГМУ; аспирант, ассистент, кафедра патологической анатомии, СибГМУ</p><p>634050, г. Томск, Московский тракт, 2</p></bio><bio xml:lang="en"><p>2, Moscow Trakt, Tomsk, 634050</p><p> </p></bio><email xlink:type="simple">serg.nau2011@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1909-1681</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Крахмаль</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Krakhmal</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Крахмаль Надежда Валерьевна – канд. мед. наук, доцент, ст. науч. сотрудник, отделение общей и молекулярной патологии, НИИ онкологии, Томский НИМЦ; доцент кафедры патологической анатомии, СибГМУ</p><p>634050, г. Томск, Московский тракт, 2,</p><p>634009, г. Томск, пер. Кооперативный, 5</p></bio><bio xml:lang="en"><p>2, Moscow Trakt, Tomsk, 634050,</p><p>5, Kooperativny Str., Tomsk, 634009</p></bio><email xlink:type="simple">krakhmal@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3878-2290</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Тарасов</surname><given-names>М. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Tarasov</surname><given-names>M. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Тарасов Михаил Николаевич – аспирант, кафедра патологической анатомии</p><p>634009, г. Томск, пер. Кооперативный, 5</p></bio><bio xml:lang="en"><p>2, Moscow Trakt, Tomsk, 634050</p></bio><email xlink:type="simple">mih.n.tarasov@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Тараненко</surname><given-names>М. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Taranenko</surname><given-names>M. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Тараненко Мария Игоревна – врач-патологоанатом, отделение общей молекулярной патологии, НИИ онкологии, Томский НИМЦ; аспирант, кафедра патологической анатомии, СибГМУ</p><p>634009, г. Томск, пер. Кооперативный, 5</p></bio><bio xml:lang="en"><p>5, Kooperativny Str., Tomsk, 634009</p></bio><email xlink:type="simple">doctor.mariya.14@gmail.com</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6104-4782</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Удут</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Udut</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Удут Елена Владимировна – д-р мед. наук, профессор РАН, зав. ЦНИЛ</p><p>634050, г. Томск, Московский тракт, 2</p></bio><bio xml:lang="en"><p>2, Moscow Trakt, Tomsk, 634050</p></bio><email xlink:type="simple">lab.cni@ssmu.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7156-2471</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Колобовникова</surname><given-names>Ю. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kolobovnikova</surname><given-names>Yu. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Колобовникова Юлия Владимировна – д-р мед. наук, доцент, зав. кафедрой нормальной физиологии, профессор кафедры патофизиологии</p><p>634050, г. Томск, Московский тракт, 2</p></bio><bio xml:lang="en"><p>2, Moscow Trakt, Tomsk, 634050</p></bio><email xlink:type="simple">kolobovnikova.julia@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1195-4008</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Вторушин</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Vtorushin</surname><given-names>S. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Вторушин Сергей Владимирович – д-р мед. наук, профессор, руководитель отделения общей и молекулярной патологии, НИИ онкологии, Томский НИМЦ; профессор кафедры патологической анатомии, СибГМУ</p><p>634050, г. Томск, Московский тракт, 2,</p><p>634009, г. Томск, пер. Кооперативный, 5</p></bio><bio xml:lang="en"><p>2, Moscow Trakt, Tomsk, 634050,</p><p>5, Kooperativny Str., Tomsk, 634009</p></bio><email xlink:type="simple">wtorushin@rambler.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Сибирский государственный медицинский университет (СибГМУ)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Siberian State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Сибирский государственный медицинский университет (СибГМУ);&#13;
Научно-исследовательский институт (НИИ) онкологии, Томский национальный исследовательский медицинский центр (НИМЦ) Российской академии наук</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Siberian State Medical University;&#13;
Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Научно-исследовательский институт (НИИ) онкологии, Томский национальный исследовательский медицинский центр (НИМЦ) Российской академии наук</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>23</day><month>01</month><year>2024</year></pub-date><volume>22</volume><issue>4</issue><fpage>57</fpage><lpage>64</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Наумов С.С., Крахмаль Н.В., Тарасов М.Н., Тараненко М.И., Удут Е.В., Колобовникова Ю.В., Вторушин С.В., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Наумов С.С., Крахмаль Н.В., Тарасов М.Н., Тараненко М.И., Удут Е.В., Колобовникова Ю.В., Вторушин С.В.</copyright-holder><copyright-holder xml:lang="en">Naumov S.S., Krakhmal N.V., Tarasov M.N., Taranenko M.I., Udut E.V., Kolobovnikova Y.V., Vtorushin S.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://bulletin.ssmu.ru/jour/article/view/5418">https://bulletin.ssmu.ru/jour/article/view/5418</self-uri><abstract><sec><title>Цель</title><p>Цель. Провести клинико-морфологическую оценку особенностей рака толстой кишки (РТК) в зависимости от dMMR/pMMR статуса.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. В исследование ретроспективно включено 66 пациентов с операбельным РТК T14bN0-2bM1, прошедших лечение в НИИ онкологии Томского НИМЦ. Средний возраст больных составил 64,4 ± 12,8 года. Всем пациентам выполнено оперативное лечение в объеме гемиколэктомии или резекции кишки, а также интраоперационная резекция отдаленных метастазов при их наличии.</p></sec><sec><title>Результаты</title><p>Результаты. Установлено, что у пациентов с РТК и pMMR статусом гематогенные метастазы определялись в 27,3% случаев, в то время как у пациентов с dMMR статусом гематогенные метастазы были обнаружены лишь в 6,1% случаев (p = 0,021). Сравнительный анализ опухолей с dMMR и pMMR статусом также позволил установить большую частоту наличия периневральной опухолевой инвазии среди pMMR подгруппы карцином (p = 0,039). Признак «опухолевого почкования» был обнаружен как в карциномах с дефицитом белков мисматч репарации (36%), так и в профицитных опухолях (45%). Данный признак был сопряжен с поражением регионарных лимфатических узлов (p = 0,0017). Более детальный анализ феномена «опухолевого почкования» показал, что в опухолях с дефицитом белков мисматч репарации преобладал первый тип почкования (Bd1) low grade – низкой степени – (83%), в то время как профицитные опухоли характеризовались преобладанием почкования второго типа (Bd2) – intermediate grade – умеренной степени (33%) и (Bd3) – high grade – высокой степени (26,7%). Феномен «опухолевого почкования» Bd2 и Bd3 был сопряжен с гематогенным метастазированием (p &lt; 0,001).</p></sec><sec><title>Заключение</title><p>Заключение. Полученные данные демонстрируют различия по таким патоморфологическим параметрам, как периневральная инвазия и степень «опухолевого почкования» в зависимости от dMMR/pMMR статуса карциномы. Данные гистологические параметры в опухолевой ткани также связаны с большей частотой встречаемости отдаленных метастазов у пациентов с карциномами со статусом pMMR в отличие от пациентов c dMMR статусом опухоли.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. To conduct a clinical and morphological assessment of the characteristics of colon cancer depending on the dMMR / pMMR status of the tumor.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. A retrospective study included 66 patients with operable colorectal cancer (CRC) (T1-4bN0-2bM1), who were treated at Cancer Research Institute of Tomsk National Research Medical Center (NRMC). The average age of the patients was 64.4 ± 12.8 years. All patients underwent hemicolectomy or colon resection, as well as intraoperative resection of distant metastases, if present.</p></sec><sec><title>Results</title><p>Results. We determined that in CRC patients with pMMR tumors, hematogenous metastases were detected in 27.3% of cases, while in patients with dMMR tumors, hematogenous metastases were detected only in 6.1% of cases (p = 0.021). A comparative analysis of dMMR and pMMR tumors also allowed to establish higher frequency of perineural invasion among the pMMR subgroup of carcinomas (p = 0.039). The sign of tumor budding was found both in dMMR carcinomas (36%) and in pMMR tumors (45%). This sign was associated with damage to regional lymph nodes (p = 0.0017). A more detailed analysis of the tumor budding phenomenon showed that in dMMR tumors, Bd1 low-grade budding (83%) predominated. In pMMR tumors, Bd2 intermediate-grade budding (33%) and Bd3 high-grade budding (26.7%) prevailed. Bd2 and Bd3 tumor budding types were associated with hematogenous metastasis (p &lt; 0.001).</p></sec><sec><title>Conclusion</title><p>Conclusion. The obtained data demonstrate the differences in such pathomorphological parameters as perineural invasion and the degree of tumor budding depending on the dMMR / pMMR status of the tumor. These histologic parameters in tumor tissue are also associated with higher incidence of distant metastasis in patients with pMMR carcinomas as opposed to patients with dMMR tumors.</p></sec><sec><title> </title><p> </p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>белки системы мисматч репарации</kwd><kwd>dMMR/pMMR статус</kwd><kwd>колоректальный рак</kwd></kwd-group><kwd-group xml:lang="en"><kwd>mismatch repair system proteins</kwd><kwd>dMMR / pMMR status</kwd><kwd>colon cancer</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A.et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021;71(3):209– 249. DOI: 10.3322/caac.21660.</mixed-citation><mixed-citation xml:lang="en">Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A.et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021;71(3):209– 249. DOI: 10.3322/caac.21660.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Каприн А.Д., Старинский В.В., Шахзадова А.О. Злокачественные новообразования в России в 2021 году (заболеваемость и смертность). М., 2022:250.</mixed-citation><mixed-citation xml:lang="en">Каприн А.Д., Старинский В.В., Шахзадова А.О. Злокачественные новообразования в России в 2021 году (заболеваемость и смертность). М., 2022:250.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Argilés G., Tabernero J., Labianca R., Hochhauser D., Salazar R., Iveson T. et al. ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Localised colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2020;31(10):1291–1305. DOI: 10.1016/j.annonc.2020.06.022.</mixed-citation><mixed-citation xml:lang="en">Argilés G., Tabernero J., Labianca R., Hochhauser D., Salazar R., Iveson T. et al. ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Localised colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2020;31(10):1291–1305. DOI: 10.1016/j.annonc.2020.06.022.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Watanabe T., Itabashi M., Shimada Y., Tanaka S., Ito Y., Ajioka Y. et al. Japanese Society for Cancer of the Colon and Rectum. Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer. Int. J. Clin. Oncol. 2015;20(2):207–239. DOI: 10.1007/s10147-015-0801-z.</mixed-citation><mixed-citation xml:lang="en">Watanabe T., Itabashi M., Shimada Y., Tanaka S., Ito Y., Ajioka Y. et al. Japanese Society for Cancer of the Colon and Rectum. Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer. Int. J. Clin. Oncol. 2015;20(2):207–239. DOI: 10.1007/s10147-015-0801-z.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Trinh A., Lädrach C., Dawson H.E., Ten Hoorn S., Kuppen P.J.K., Reimers M.S. et al. Tumour budding is associated with the mesenchymal colon cancer subtype and RAS/RAF mutations: a study of 1320 colorectal cancers with Consensus Molecular Subgroup (CMS) data. Br. J. Cancer. 2018;119(10):1244– 1251. DOI: 10.1038/s41416-018-0230-7.</mixed-citation><mixed-citation xml:lang="en">Trinh A., Lädrach C., Dawson H.E., Ten Hoorn S., Kuppen P.J.K., Reimers M.S. et al. Tumour budding is associated with the mesenchymal colon cancer subtype and RAS/RAF mutations: a study of 1320 colorectal cancers with Consensus Molecular Subgroup (CMS) data. Br. J. Cancer. 2018;119(10):1244– 1251. DOI: 10.1038/s41416-018-0230-7.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Basile D., Broudin C., Emile J.F., Falcoz A., Pagès F., Mineur L. et al. For PRODIGE investigators, GERCOR, Fédération Française de Cancerologie Digestive, and UNICANCER. Tumor budding is an independent prognostic factor in stage III colon cancer patients: a post-hoc analysis of the IDEAFrance phase III trial (PRODIGE-GERCOR). Ann. Oncol. 2022;33(6):628–637. DOI: 10.1016/j.annonc.2022.03.002.</mixed-citation><mixed-citation xml:lang="en">Basile D., Broudin C., Emile J.F., Falcoz A., Pagès F., Mineur L. et al. For PRODIGE investigators, GERCOR, Fédération Française de Cancerologie Digestive, and UNICANCER. Tumor budding is an independent prognostic factor in stage III colon cancer patients: a post-hoc analysis of the IDEAFrance phase III trial (PRODIGE-GERCOR). Ann. Oncol. 2022;33(6):628–637. DOI: 10.1016/j.annonc.2022.03.002.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Eso Y., Shimizu T., Takeda H., Takai A., Marusawa H. Microsatellite instability and immune checkpoint inhibitors: toward precision medicine against gastrointestinal and hepatobiliary cancers. J. Gastroenterol. 2020;55(1):15–26. DOI: 10.1007/s00535-019-01620-7.</mixed-citation><mixed-citation xml:lang="en">Eso Y., Shimizu T., Takeda H., Takai A., Marusawa H. Microsatellite instability and immune checkpoint inhibitors: toward precision medicine against gastrointestinal and hepatobiliary cancers. J. Gastroenterol. 2020;55(1):15–26. DOI: 10.1007/s00535-019-01620-7.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Battaglin F., Naseem M., Lenz H.J., Salem M.E. Microsatellite instability in colorectal cancer: overview of its clinical significance and novel perspectives. Clin. Adv. Hematol. Oncol. 2018;16(11):735–745.</mixed-citation><mixed-citation xml:lang="en">Battaglin F., Naseem M., Lenz H.J., Salem M.E. Microsatellite instability in colorectal cancer: overview of its clinical significance and novel perspectives. Clin. Adv. Hematol. Oncol. 2018;16(11):735–745.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Bromham N., Kallioinen M., Hoskin P., Davies R.J. Guideline Committee. Colorectal cancer: summary of NICE guidance. BMJ. 2020;368:461. DOI: 10.1136/bmj.m461.</mixed-citation><mixed-citation xml:lang="en">Bromham N., Kallioinen M., Hoskin P., Davies R.J. Guideline Committee. Colorectal cancer: summary of NICE guidance. BMJ. 2020;368:461. DOI: 10.1136/bmj.m461.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Gelsomino F., Barbolini M., Spallanzani A., Pugliese G., Cascinu S. The evolving role of microsatellite instability in colorectal cancer: A review. Cancer Treat Rev. 2016;51:19–26. DOI: 10.1016/j.ctrv.2016.10.005.</mixed-citation><mixed-citation xml:lang="en">Gelsomino F., Barbolini M., Spallanzani A., Pugliese G., Cascinu S. The evolving role of microsatellite instability in colorectal cancer: A review. Cancer Treat Rev. 2016;51:19–26. DOI: 10.1016/j.ctrv.2016.10.005.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Федянин М.Ю., Гладков О.А., Гордеев С.С., Карачун А.М., Козлов Н.А., Мамедли З.З. Практические рекомендации по лекарственному лечению рака ободочной кишки, ректосигмоидного соединения и прямой кишки. Злокачественные опухоли: Практические рекомендации RUSSCO № 3(2). 2022;(12):401–454.</mixed-citation><mixed-citation xml:lang="en">Федянин М.Ю., Гладков О.А., Гордеев С.С., Карачун А.М., Козлов Н.А., Мамедли З.З. Практические рекомендации по лекарственному лечению рака ободочной кишки, ректосигмоидного соединения и прямой кишки. Злокачественные опухоли: Практические рекомендации RUSSCO № 3(2). 2022;(12):401–454.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Yang G., Zheng R.Y., Jin Z.S. Correlations between microsatellite instability and the biological behaviour of tumours. J. Cancer Res. Clin. Oncol. 2019;145(12):2891–2899. DOI: 10.1007/s00432-019-03053-4.</mixed-citation><mixed-citation xml:lang="en">Yang G., Zheng R.Y., Jin Z.S. Correlations between microsatellite instability and the biological behaviour of tumours. J. Cancer Res. Clin. Oncol. 2019;145(12):2891–2899. DOI: 10.1007/s00432-019-03053-4.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Lin A., Zhang J., Luo P. Crosstalk between the MSI status and tumor microenvironment in colorectal cancer. Front. Immunol. 2020;11:2039. DOI: 10.3389/fimmu.2020.02039.</mixed-citation><mixed-citation xml:lang="en">Lin A., Zhang J., Luo P. Crosstalk between the MSI status and tumor microenvironment in colorectal cancer. Front. Immunol. 2020;11:2039. DOI: 10.3389/fimmu.2020.02039.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Smyth E.C., Wotherspoon A., Peckitt C., Gonzalez D., Hulkki-Wilson S., Eltahir Z. et al. Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial. JAMA Oncol. 2017;3(9):1197–1203. DOI: 10.1001/jamaoncol.2016.6762.</mixed-citation><mixed-citation xml:lang="en">Smyth E.C., Wotherspoon A., Peckitt C., Gonzalez D., Hulkki-Wilson S., Eltahir Z. et al. Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial. JAMA Oncol. 2017;3(9):1197–1203. DOI: 10.1001/jamaoncol.2016.6762.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
